Cartesian Therapeutics IncNASDAQ:RNAC
- LAST PRICE16.1200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots15.8000/ 10
- Ask / Lots17.0000/ 3
- Open / Previous Close--- / 16.1200
- Day Range---
- 52 Week Range
- Volume105
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RNAC |
|---|---|---|
| 09:32 ET | 412 | 14.91 |
| 09:34 ET | 875 | 14.75 |
| 09:36 ET | 3608 | 14 |
| 09:50 ET | 250 | 14.9947 |
| 09:57 ET | 402 | 14.75 |
| 09:59 ET | 147 | 14.75 |
| 10:14 ET | 500 | 15.17 |
| 10:17 ET | 245 | 15.135 |
| 10:37 ET | 100 | 15.11 |
| 10:46 ET | 100 | 14.885 |
| 10:50 ET | 1008 | 15.115 |
| 10:51 ET | 100 | 14.94 |
| 10:53 ET | 100 | 14.87 |
| 10:55 ET | 100 | 14.94 |
| 11:09 ET | 840 | 14.93 |
| 11:11 ET | 600 | 14.845 |
| 11:13 ET | 1300 | 14.7129 |
| 11:56 ET | 2616 | 14.92 |
| 11:58 ET | 4690 | 14.98 |
| 12:00 ET | 1360 | 15.1 |
| 12:02 ET | 5689 | 15 |
| 12:18 ET | 100 | 14.975 |
| 12:34 ET | 1000 | 15.15 |
| 12:39 ET | 200 | 15.285 |
| 12:50 ET | 2003 | 15.61 |
| 01:06 ET | 100 | 15.605 |
| 01:35 ET | 300 | 15.6108 |
| 01:39 ET | 800 | 15.61 |
| 01:42 ET | 200 | 15.74 |
| 01:46 ET | 834 | 15.75 |
| 01:57 ET | 300 | 15.92 |
| 02:27 ET | 100 | 15.835 |
| 02:40 ET | 154 | 15.895 |
| 02:42 ET | 1603 | 16.06 |
| 03:02 ET | 501 | 16.31 |
| 03:03 ET | 200 | 16.55 |
| 03:05 ET | 1738 | 16.47 |
| 03:07 ET | 1300 | 16.425 |
| 03:12 ET | 1100 | 16.7 |
| 03:20 ET | 1100 | 16.605 |
| 03:25 ET | 1040 | 16.6 |
| 03:27 ET | 100 | 16.605 |
| 03:34 ET | 100 | 16.67 |
| 03:36 ET | 815 | 16.6 |
| 03:38 ET | 1028 | 16.6 |
| 03:39 ET | 3077 | 16.55 |
| 03:54 ET | 200 | 16.17 |
| 03:56 ET | 500 | 16.31 |
| 03:57 ET | 200 | 16.175 |
| 03:59 ET | 9218 | 16.12 |
Sep 13, 2024
DJ Cartesian Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co., from 6:38AM ET on Friday Sep 13, 2024 by Dow Jones
6:38AM ET on Friday Sep 13, 2024 by Dow Jones
Sep 9, 2024
DJ Cartesian Therapeutics Gets FDA Rare Pediatric Disease Designation for Dermatomyositis Treatment, from 7:31AM ET on Monday Sep 09, 2024 by Dow Jones
7:31AM ET on Monday Sep 09, 2024 by Dow JonesCartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow Jones
Sep 6, 2024
Cartesian Therapeutics Announces New Employment Inducement Grant, from 7:05AM ET on Friday Sep 06, 2024 by Dow Jones
7:05AM ET on Friday Sep 06, 2024 by Dow Jones
Sep 4, 2024
DJ Cartesian Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co., from 7:22AM ET on Wednesday Sep 04, 2024 by Dow Jones
7:22AM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cartesian Therapeutics Inc | 344.7M | -0.4x | --- |
Capricor Therapeutics Inc | 296.1M | -9.8x | --- |
Artiva Biotherapeutics Inc | 311.4M | 0.0x | --- |
TScan Therapeutics Inc | 270.2M | -4.9x | --- |
MeiraGTx Holdings PLC | 311.1M | -2.7x | --- |
Iteos Therapeutics Inc | 370.0M | -3.4x | --- |
Company Information
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Contact Information
- Headquarters
- 704 Quince Orchard RdGAITHERSBURG, MD, United States 20878
- Phone
- 617-923-1400
- Fax
- 617-924-3454
Executives
- Independent Chairman of the Board
- Carrie Cox
- President, Chief Executive Officer, Director
- Carsten Brunn
- Chief Financial Officer
- Blaine Davis
- Senior Vice President, Head of Manufacturing Operations
- Emily English
- Chief Technology Officer
- Metin Kurtoglu
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $344.7M |
|---|---|
Revenue (TTM) | $54.1M |
Shares Outstanding | 21.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.64 |
EPS | $-38.41 |
Book Value | $-25.87 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 6.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -90.55% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
